Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RxSight (RXST) Free Cash Flow (2020 - 2025)

RxSight (RXST) has disclosed Free Cash Flow for 6 consecutive years, with -$1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 561.32% year-over-year to -$1.4 million, compared with a TTM value of -$15.9 million through Dec 2025, up 8.91%, and an annual FY2025 reading of -$15.9 million, up 8.91% over the prior year.
  • Free Cash Flow was -$1.4 million for Q4 2025 at RxSight, down from -$1.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$212000.0 in Q4 2024 and bottomed at -$18.5 million in Q1 2023.
  • Average Free Cash Flow over 5 years is -$9.1 million, with a median of -$8.8 million recorded in 2021.
  • The sharpest move saw Free Cash Flow surged 97.47% in 2024, then crashed 561.32% in 2025.
  • Year by year, Free Cash Flow stood at -$8.6 million in 2021, then tumbled by 87.51% to -$16.1 million in 2022, then soared by 47.99% to -$8.4 million in 2023, then soared by 97.47% to -$212000.0 in 2024, then plummeted by 561.32% to -$1.4 million in 2025.
  • Business Quant data shows Free Cash Flow for RXST at -$1.4 million in Q4 2025, -$1.1 million in Q3 2025, and -$4.4 million in Q2 2025.